Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S.
Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74. Epub 2006 Dec 8.PMID: 17160391 [PubMed - indexed for MEDLINE]Related articles